Why this ASX cannabis share is shooting 15% higher today

The Medlab Clinical Ltd (ASX:MDC) share price is shooting higher on Monday despite the market selloff. Here's why this cannabis share is on a high…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be sinking lower again on Monday, but that hasn't stopped the Medlab Clinical Ltd (ASX: MDC) share price from charging higher.

The cannabis-focused biotech company's shares are up 15.5% to 26 cents in morning trade.

Why is the Medlab share price charging higher?

Investors have been buying Medlab's shares this morning following the release of an independent review of its NanaBis advanced cancer pain trial conducted at the Royal North Shore Hospital (RNSH).

The clinical trial was a Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) investigation into pain management of patients with metastatic cancers.

According to the release, the trial met its primary endpoints and found that NanaBis is tolerable, efficacious, fast acting, and delivered improvements in quality of life measures. This was particularly the case in role and emotional functioning and insomnia.

In addition to this, secondary endpoints were met. This includes a meaningful pain reduction and significantly less morphine milliequivalent of dispensed opioid analgesics prescribed for breast or prostate cancers with bone metastasis.

Management believes this was a robust trial that has delivered strong results and allows it to focus on Phase 3 designs.

Dr Sean Hall, CEO of Medlab, advised, "With a strong trial design, that involved a professional and strong clinical trial team and collaborators, today we have primary evidence that NanaBis is safe, tolerable and provided a significant benefit in managing pain associated with metastatic cancers."

"There were a number of notable secondary gains, one of the biggest worth mentioning was a drastic reduction of breakthrough medication used by those patients with breast or prostate cancers with bone METs."

Dr Hall concluded: "We can confidently argue, NanaBis has a strong indication for use in pain management and is a compelling therapy for this patient group."

It is still very early days, but there is a potentially big opportunity for the product if everything goes to plan. The company notes that metastatic breast or prostate cancers have a high unmet need, with conservative 2017 numbers suggesting 600,000 patients in USA, Canada, Europe, and Australia.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors finished the trading week on a high note this Friday.

Read more »

Happy teen friends jumping in front of a wall.
Share Gainers

4 ASX 200 shares leading the charge higher this week

Investors have been piling into these four ASX 200 shares this week. But why?

Read more »

A happy investor sits at his desk in front of his laptop and does the mexican wave with his arms to celebrate the returns from his ASX dividend shares
Share Gainers

Why Catapult, Champion Iron, Healthco, and Meeka Metals shares are pushing higher today

These shares are ending the week on a high. But why?

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors saw another day of mild gains for the stock market this Thursday.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Champion Iron, Clarity Pharmaceuticals, St Barbara, and Woodside shares are charging higher today

These shares are having a good session today. But why are investors buying them?

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors panicked when the latest inflation figures came out today.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Mac Copper, Pro Medicus, Web Travel, and Yancoal shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »

Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a pleasant Tuesday session for ASX investors today.

Read more »